Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-05
2011-07-05
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07973052
ABSTRACT:
Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R2is alkyl having from 1 to 3 carbon atoms; R3is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms;A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon; and R1is hydrogen or alkyl having 1 or 2 carbon atoms, provided that when m is 0 or 1, R1is not hydrogen. Alternatively, when R1is hydrogen, the biologically active agent can be a pharmaceutically acceptable salt of the compound of Formula I.
REFERENCES:
patent: 3048633 (1962-08-01), Russell et al.
patent: 5132328 (1992-07-01), Girodeau et al.
patent: 5219579 (1993-06-01), Tisdale et al.
patent: 5604225 (1997-02-01), Reiffen et al.
patent: 5665387 (1997-09-01), Mathieu et al.
patent: 6143787 (2000-11-01), Moinet et al.
patent: 6156781 (2000-12-01), Talley et al.
patent: 6307080 (2001-10-01), Pischel et al.
patent: 6858602 (2005-02-01), Sharma et al.
patent: 6916848 (2005-07-01), Sharma
patent: 6924314 (2005-08-01), Sharma et al.
patent: 6946491 (2005-09-01), Sharma et al.
patent: 7012071 (2006-03-01), Sharma et al.
patent: 7041659 (2006-05-01), Sharma
patent: 7045541 (2006-05-01), Sharma
patent: 7101910 (2006-09-01), Sharma
patent: 7329782 (2008-02-01), Sharma et al.
patent: 7361686 (2008-04-01), Hodge et al.
patent: 7442796 (2008-10-01), Sharma et al.
patent: 7514555 (2009-04-01), Hodge et al.
patent: 2002/0028943 (2002-03-01), Griffin
patent: 2005/0090555 (2005-04-01), Sharma et al.
patent: 2006/0035970 (2006-02-01), Hodge et al.
patent: 2006/0247309 (2006-11-01), Hodge et al.
patent: 2007/0105958 (2007-05-01), Sharma et al.
patent: 2007/0249696 (2007-10-01), Sharma et al.
patent: 2007/0249719 (2007-10-01), Sharma et al.
patent: 2007/0265322 (2007-11-01), Sharma et al.
patent: 2007/0282003 (2007-12-01), Sharma et al.
patent: 2008/0015209 (2008-01-01), Sharma et al.
patent: 2008/0015254 (2008-01-01), Sharma et al.
patent: 2008/0021109 (2008-01-01), Sharma et al.
patent: 2008/0027229 (2008-01-01), Hodge et al.
patent: 2008/0306150 (2008-12-01), Sharma et al.
patent: 2008/0306165 (2008-12-01), Sharma et al.
patent: 2009/0005451 (2009-01-01), Hodge et al.
patent: 0375368 (1990-06-01), None
patent: 1422224 (2004-05-01), None
patent: 1482195 (1977-08-01), None
patent: 2177600 (1987-01-01), None
patent: 57150633 (1982-09-01), None
patent: 62-61587 (1987-03-01), None
patent: 3-135936 (1991-06-01), None
patent: 7-503459 (1995-04-01), None
patent: 2002-509923 (2002-04-01), None
patent: 2003-64065 (2003-03-01), None
patent: 93/14077 (1993-07-01), None
patent: 99/50254 (1999-10-01), None
patent: 02/100341 (2002-12-01), None
patent: 2004/041165 (2004-05-01), None
patent: 2006/012133 (2004-05-01), None
patent: 2004/073611 (2004-09-01), None
patent: 2004/091486 (2004-10-01), None
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,515.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,520.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,560.
Pending (as of Jul. 14, 2008) claims from U.S. Appl. No. 12/160,857.
Pending (as of Jul. 28, 2008) claims from U.S. Appl. No. 12/162,397.
Pending (as of May 7, 2008) claims from U.S. Appl. No. 12/092,932.
Pending (as of Aug. 13, 2008) claims from U.S. Appl. No. 12/279,247.
Pending (as of Aug. 18, 2008) claims from U.S. Appl. No. 12/279,808.
Pending (as of Sep. 25, 2008) claims from U.S. Appl. No. 12/294,530.
Pending (as of Dec. 9, 2008) claims from U.S. Appl. No. 12/300,239.
Pending (as of Dec. 8, 2008) claims from U.S. Appl. No. 12/304,007.
Pending (as of Feb. 13, 2009) claims from U.S Appl. No. 12/377,460.
Younis, et al., “The prevention of type 2 diabetes mellitus: recent advances”, QJ Med., 97: 451-455, 2004.
Goff, et al., “Prevention of Cardiovascular Disease in Persons with type 2 diabetes Mellitus: Current Knowledge and Rational for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial”, AM J Cardiol., 99(12A): S4-S20, 2007. (Abstract).
Knowler, et al., “Perspectives in Diabetes: Preventing Non-Insulin-Dependent Diabetes”, Diabetes, 44: 483-488, 1995.
Kilpatrick, et al. “Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes”, Diabetes Care, vol. 30, No. 3, pp. 707-712, Mar. 2007.
Friedman, et al., “Impaired Glucose Transport and Insulin Receptor Tyrosine Phosphorylation in Skeletal Muscle From Obese Women with Gestational Diabetes”, Diabetes, vol. 48, pp. 1807-1814, Sep. 1999.
Child, et al., “Fenbufen, a New Anti-Inflammatory Analgesic: Synthesis and Structure-Activity Relationships of Analogs”, Journal of Pharmaceutical Sciences, 1977, 66(4), pp. 466-476.
Connolly, et al., “Design and Synthesis of a Novel and Potent Series of Inhibitors of Cytosolic Phospholipase A2 Based on a 1,3-Disubstituted Propan-2-one Skeleton”, Journal of Medicinal Chemistry, 2002, 45(6), pp. 1348-1362.
Flynn, et al., “One-Pot Synthesis of Benzol[b]furan and Indole Inhibitors of Tubulin Polymerization”, Journal of Medicinal Chemistry, 2002, 45(12), pp. 2670-2673.
Argiles, et al., “Journey from cachexia to obesity by TNF”, The FASEB Journal, 1997, 11(10), pp. 743-751. (Abstract).
de Alvaro, et al., “Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner”, J. Biol. Chem., 2004, 279(17), pp. 17070-17078. (Abstract).
Rofe, et al, “Altered insulin response to glucose in weight-losing cancer patients”, Anticancer Research, 1994, 14(2B); pp. 647-650. (Abstract).
Tayek, “A review of cancer cachexia and abnormal glucose metabolism in humans with cancer”, Journal of the American College of Nutrition, 1992, 11(4), pp. 445-456. (Abstract).
Wedick, et al., “Insulin resistance precedes weight loss in adults without diabetes: the Rancho Bernardo Study”, American Journal of Epidemiology, 2001, 153(12), pp. 1199-1205. (Abstract).
Notification of Reexamination dated Jul. 1, 2009 in Chinese Patent Application No. 200480010105.X.
English language translation of JP 62-61587, (1987).
Sohda, et al., “Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)benzyllthiazolidine-2,4-dione (ADD-3878) and its derivatives”,Chemical & Pharmaceutical Bulletin, 30(10): 3580-3600, 1982.
Poupardin, et al.,“First approach to the cycloisodityrosine unit of RA-IV”, Tetrahedron Letters, 42(8):1523-1526, 2001.
Sato, et al., “A General Method for the Formation of Zinc Enolate Equivalents from lodoacetates by DiisopropylzincIodine Exchange Reaction: Preparation of β-Hydroxy Esters”, Bulletin of the Chemical Society of Japan, 73(12): 2825-2826, 2000.
Ciofi-Baffoni, et al, “Synthesis of oligomeric mimics of lignin”, Journal of the Chemical Society, Perkin Transactions, Organic and Bio-Organic Chemistry, 1: 3207-3218, 1998.
Fadnavis, et al., “Baker's yeast mediated enantiospecific synthesis of anti-(2R,3R)-p-chloro-3-hydroxytyrosine: an α-amino-β-hydroxy acid of vancomycin”, Tetrahedron: Asymmetry, 8(24): 4003-4006, 1997.
Girard, et al. Syntheses of the syn and anti α-amino-β-hydroxy acids of vancomycin: (2S,3R) and (2R,3R) p-chloro-3-hydroxytyrosi
Hodge Kirvin L.
Sharma Shalini
von Borstel Reid W.
Wolpe Stephen D.
Kreisler Lewis J.
Weddington Kevin
Wellstat Therapeutics Corporation
LandOfFree
Compounds for the treatment of metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of metabolic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649169